Clozapine Titration Schedule
Start clozapine at 12.5 mg once or twice daily, increase by 25-50 mg per day if tolerated, targeting 300-450 mg/day in divided doses by the end of 2 weeks, with subsequent increases of 100 mg or less once or twice weekly up to a maximum of 900 mg/day. 1
Standard FDA-Approved Titration
The FDA label provides the definitive titration schedule 1:
- Initial dose: 12.5 mg once or twice daily
- Titration rate: Increase total daily dose by 25-50 mg/day if well-tolerated
- Target by week 2: 300-450 mg/day in divided doses
- Subsequent increases: 100 mg or less, once or twice weekly
- Maximum dose: 900 mg/day
This slow, cautious titration with divided dosing is critical because orthostatic hypotension, bradycardia, syncope, and cardiac arrest can occur with the first dose, with doses as low as 12.5 mg/day, or when restarting after even brief interruptions 1. The risk is highest during initial titration, particularly with rapid dose escalation.
Pediatric Populations
For children and adolescents, the NIMH protocol uses weight-based starting doses of 6.25-25 mg/day depending on patient weight 2. In adults, the standard is 12.5 mg once or twice daily with increases of no more than 25-50 mg added to the total daily dose once or twice per week 2.
Emerging Personalized Approaches
Recent international guidelines propose ancestry-based personalized titration schedules, though these are not yet incorporated into FDA labeling 3, 4, 5:
- Asian ancestry or Indigenous Americans: Lower metabolism requires minimum therapeutic doses of 75-300 mg/day depending on sex, smoking status, and poor metabolizer (PM) status
- European/Western Asian ancestry: Average metabolism requires 250-400 mg/day; PM status requires 100-200 mg/day
- Other ancestries in the US: 300-600 mg/day for average metabolism; 150-300 mg/day for PM status
These personalized schedules account for three levels of complexity: ancestry groups, sex-smoking subgroups, and PM status (from obesity, valproate, oral contraceptives, or inflammation) 3, 4.
Critical Monitoring During Titration
Measure C-reactive protein (CRP) at baseline and weekly for at least the first 4 weeks to identify inflammation that may indicate clozapine-induced myocarditis or pneumonia 3, 4, 6. Elevated CRP during titration suggests either clozapine-induced inflammation from too-rapid titration for that patient's metabolism, or concurrent infection 6.
Weekly absolute neutrophil count (ANC) monitoring is mandatory for the first 6 months, then every 2 weeks thereafter 2. Baseline ANC must be at least 1500/μL (or 1000/μL for documented Benign Ethnic Neutropenia) 1.
Therapeutic Targets
Target clozapine plasma levels of at least 350 ng/mL for therapeutic response 7. If positive symptoms persist after 12 weeks at therapeutic levels, consider increasing to 550 ng/mL 7. The therapeutic reference range is narrow (350-600 ng/mL), with increasing toxicity risk at higher concentrations 4.
Common Pitfalls
- Rapid titration: Increases risk of orthostatic hypotension, myocarditis, and pneumonia—the latter causes four times more deaths than agranulocytosis or myocarditis 4
- Ignoring metabolic factors: Obesity, valproate co-prescription, oral contraceptives, and inflammation all reduce clozapine metabolism, requiring slower titration 3, 4
- Missing inflammation: CRP monitoring can identify early myocarditis or pneumonia risk 3, 6
- Inadequate trial duration: Require at least 4-6 weeks at therapeutic doses before declaring treatment failure 2
Rechallenge After Interruption
Restart at 12.5 mg once or twice daily even after brief interruptions (>48 hours), as reactions can occur with restarting 1. Clozapine shows low forgiveness for missed doses—eight consecutively missed doses drop levels to near zero 8.